PI3K inhibitor treatment of patients with ER+ breast cancer for ≥14 d induces upregulation of tumor ER levels and activity [43], which Toska et al. recently demonstrated is mediated by loss of AKT-induced epigenetic silencing of ER activity [44]. Here, ESR1 is linked to neoplasm.